News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

A Closer Look At Amgen (AMGN)'s Money Back Guarantee For Repatha



4/4/2017 6:28:48 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
The high cost of drugs continues to dominate the news in the biopharmaceutical industry. Recent data for new cancer drugs that upregulate the immune system to fight melanoma, lung cancer, etc. are very promising. Yet, stories on these wonder drugs quickly dive into their costs – justifiably so. For example, Bristol-Myers Squibb’s combination of Opdivo and Yervoy can cost up to $21,000 – a month! But, new cancer therapies are not unique with respect to pricing. Similar stories can be found with drugs to treat rare diseases, hepatitis C, multiple sclerosis, etc.

Read at Forbes


comments powered by Disqus
Forbes
Amgen
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES